Danish Biotech Weekly – Week 21
Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider
22. May 2023
Front page> Investment cases> CS Medica
CS Medica is a Danish MedTech/biotech company focusing on the treatment of pain, stress and autoimmune diseases with CBD (non-euphoriant substance from the cannabis plant) as a primary ingredient. The products are sold under the brand name CANNASEN to pharmacies and retail chains such as Matas, and as OEM to pharmaceutical companies and manufacturers. Several of CS Medical’s products are probably the only CBD products registered as “medical devices” under the European MDD Directive, which gives the company a first mover advantage in CBD-based products.
CS Medical is listed on the Spotlight Stock Market with the ticker “CSMED”.
Sales of cannabis products are growing rapidly as a result of global liberalization and legalization. Sales of products containing the non-euphoriant substance, CBD, are also experiencing high global growth rates, although there are still few standardized, registered or approved products on the market. The growth of CBD products is also due to the general and increasing trend/demand for effective and alternative OTC products with fewer ingredients and side effects than traditional medicine.
CS Medica is a MedTech/biotech company focused on developing, patenting and selling CBD-based products and is probably the only manufacturer of CBD products registered under the European MDD Directive. The MDD is being replaced by the MDR regulation, and new products will have to wait for the existing tens of thousands of MDD registered products to be registered under the MDR. Already registered products therefore have a significant market advantage over new products entering the market, which gives CS Medica a unique market position.
Potential of CS Medica:
Risks:
Price triggers:
H1 2023
H2 2023
Cannabis and CBD in global growth
The use of cannabis products is growing rapidly globally as a result of liberalization and legalization, both for products containing the euphoriant substance THC and the sedative/painkiller CBD. CBD-based products, including CBD oils, are increasingly being used as an alternative to traditional painkillers, particularly by cancer and chemotherapy patients. It is expected that the use of CBD-based products for many different indications will grow globally as a result of the launch of products that have been tested, registered or approved as medicines, etc. and as a result of a growing consumer trend towards alternative over-the-counter products with fewer ingredients and side effects than conventional medicine/treatment.
First mover advantage in a global market
CS Medica is a MedTech/biotech company that develops and sells CBD-based (non-euphoriant substance from the cannabis plant) products – currently focusing on, among other things, the treatment of pain, stress and autoimmune diseases such as arthritis and psoriasis. With the exception of the cosmetic/cosmeceuticals products, the products are registered as “Medical Devices” under the European MDD Directive. CS Medica is probably the only company to have achieved this. This gives CS Medica a first mover advantage over other manufacturers, while at the same time, due to the ongoing transition from MDD to MDR regulation, CS Medica will be the only manufacturer of CBD products registered under the MDR, while registered products from other manufacturers are unlikely to enter the market in the coming years.
The opportunity to be first with CBD preparations approved under the MDR gives CS Medica a unique opportunity to sell its products to large and international pharmaceutical companies that do not have these products themselves but require the products to be registered under the MDR.
Products and Pipeline
Sales and growth
In its first year as a listed company (2021/22), CS Medica had a turnover of approximately DKK 11 million. The company has set a strategy to grow its sales via:
CS MEDICA ("CS MEDICA" or "the Company") is pleased to announce the initiation of the registration process for its six medical devices in Malaysia. This initiative is undertaken in partnership with Rongshi MEDICA Co. Ltd.("RongShi Medica" or the "Joint Venture"). [image] Following our invastigation into the Asian market space, while commiting to regulatory compliance and market exploration, CS MEDICA and […]
CS MEDICA and RongShi strengthened the progress of their Joint Venture on its second Joint Fair at CPHI & PMEC in Guangzhou ,China 2023 (September 4-6), Asia's premier pharma event. [image] CS MEDICA, a leading MedTech company specializing in Cannabis and Pain Management, is excited to provide an update of its Joint Venture, RongShi MEDICA (Ordos) Co., Ltd. ("RongShi MEDICA", […]
CS MEDICA proudly announces the issue of a patent on its “Nasal Night Spray” which provides relief to congestion during the night. CS MEDICA A/S (“CS MEDICA” or “The Company”), an innovator in the healthcare industry specializing in cannabidiol (CBD) and pain management, proudly announces a significant achievement in its ongoing commitment to revolutionizing categories related to its targeting symptoms of […]
CS MEDICA (”CS MEDICA” or the ”Company”) hereby releases its Q3 report for the period April – June 2023. Highlights of the period will be presented at a live-streamed conference call on Tuesday the 8nd of August at 10 AM CET. The Q3 report is available as an attached document to this press release and on the Company's website (www.cs-medica.com). […]
CS MEDICA A/S (“CS MEDICA” or the “Company”), a MedTech company specializing in Cannabis and pain management, is thrilled to announce the establishment of CANNORDIC India Pvt. Ltd is final. The Indian subsidiary is located at B-007, Param Tower CHS Ltd, Raghunath Nagar, Survewadi, Thane West-400604. On April 14, 2023, the Company announced that its board of directors approved setting up […]
CS MEDICA Signs Contract on its Popular Pain Patch for the Spanish and Portuguese Markets and Ensures an Order of 45.000 Units. CS MEDICA A/S (“CS MEDICA” or “The Company”), a global MedTech company specializing in CBD and Pain Management, announces today the Company has received an order covering the unique product formulation for the Pain Patch (8 pieces) in […]
Today, CS MEDICA A/S announces it has secured trademark approval for its brand name CANNASEN® in Canada. A significant milestone for the company’s global footprint and in strengthening its brand recognition globally. CS MEDICA A/S (“CS MEDICA” or “The Company”), a global MedTech company specializing in CBD and pain management, is proud to take one step closer to the Canadian […]
CS MEDICA, Pioneering the Transition to MDR, Sign Contract with a Notified Body in Europe, Safeguarding Their Medical Device Product Line's Market Presence CS MEDICA A/S (“CS MEDICA” or “The Company”), a global MedTech company specializing in relieving symptoms of autoimmune diseases and stress-related disorders, is a first mover of CE-marked medical devices with CBD in the MDR (Medical Device […]
The shareholders of CS MEDICA A/S ("CS MEDICA" or the "Company") are hereby notified of an Extraordinary General Meeting that will be held on Friday the 30[th] of June 2023 at 15:00 at TEAMS. Shareholders will be entitled to vote by submitting postal vote forms prior to the meeting. Information about the resolutions passed at the meeting will be made […]
CS MEDICA A/S will deliver 45.500 pain patches in July to customers and thus faster than expected and have signed new distributors in new regions with an estimated order value of 5.6M DKK in the first contract year. CS MEDICA A/S (“CS MEDICA” or the “Company”) is happy to announce that the order intake from Q1 on the Pain Patch […]
Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider
Despite a revenue in H1 22/23 of DKK 0.3 million (DKK 0.2 million) CS Medica maintains the expectation for the year’s revenue growth of 120-130%
In the Danish Biotech Weekly, we give you insights into the Danish biotech stocks. We follow the small and established ones at home and abroad.
CS Medica has achieved positive results of a clinical study with its pain patch with CBD. With clinical proof of efficacy, the possibilities are fot
In the past week several companies announced updates to their clinical trial updates that usually acts as price trigger events for the share price. Furthermore,
The past week Gubra A/S went public on the main stock exchange in Copenhagen, raising 500 MDKK. The share price for Gubra is currently trading
Front page> Investment cases> CS Medica
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.